SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction
Portfolio Pulse from Benzinga Newsdesk
SciSparc has received FDA approval to begin a pivotal Phase IIb trial for its Tourette Syndrome treatment, SCI-110, in the U.S. This follows promising Phase IIa results showing up to 40% reduction in tics.
September 30, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc has received FDA approval to start a Phase IIb trial for its Tourette Syndrome treatment, SCI-110, in the U.S. This follows successful Phase IIa results.
The FDA approval for the Phase IIb trial is a significant milestone for SciSparc, indicating progress in their drug development pipeline. The promising Phase IIa results, showing up to 40% reduction in tics, suggest potential efficacy of the treatment, which could lead to positive investor sentiment and a potential increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100